Zacks Small Cap Forecasts Stronger Earnings for Cingulate

Cingulate Inc. (NASDAQ:CING) – Analysts at Zacks Small Cap lifted their FY2024 earnings per share estimates for shares of Cingulate in a note issued to investors on Tuesday, November 12th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings of ($9.50) per share for the year, up from their previous estimate of ($16.00). The consensus estimate for Cingulate’s current full-year earnings is ($12.51) per share. Zacks Small Cap also issued estimates for Cingulate’s Q4 2024 earnings at ($1.49) EPS, FY2025 earnings at ($2.33) EPS and FY2026 earnings at ($0.27) EPS.

Cingulate Stock Performance

Shares of NASDAQ CING opened at $4.33 on Thursday. Cingulate has a 52-week low of $1.80 and a 52-week high of $152.40. The stock’s fifty day simple moving average is $4.78 and its 200 day simple moving average is $3.03.

Cingulate (NASDAQ:CING) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.83) EPS for the quarter, topping analysts’ consensus estimates of ($2.22) by $0.39.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cingulate stock. Armistice Capital LLC purchased a new stake in Cingulate Inc. (NASDAQ:CING) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 490,000 shares of the company’s stock, valued at approximately $157,000. Armistice Capital LLC owned 6.67% of Cingulate at the end of the most recent reporting period. 41.31% of the stock is currently owned by institutional investors.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.